All In Biotech

Drug Trial Radar · NCT07230132

Efficacy and Safety of ZT006 in Overweight and Obese Participants

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Various Doses of ZT006 in Overweight and Obese Participants

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 184 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

184

Actual

Start

Dec 12, 2025

Primary completion

Dec 12, 2026

Study completion Mar 31, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the efficacy and safety of ZT006 tablet in participants with overweight and obesity. In addition to dietary caloric restriction and increased physical activity, study participants will receive either ZT006 tablets or placebo tablets once every morning (placebo looks like ZT006 tablets but has no active pharmaceutical ingredients). For a fair comparison, study participants are assigned to ZT006 or placebo randomly by a computer. The study consists of a main study and an extension period. The treatment of the main study will last for 28 weeks. ZT006 tablets will be administered daily in an up-titration fashion, i.e. the dose of ZT006 will be gradually increased to reach three target doses (low, medium, high) so that the participants can tolerate its effect. Participants will have 17 clinic visits including one screening visit and one follow-up visit. The extension study will be conducted only in participants assigned to the low and medium dose groups in the main study. The treatment of the extension period will be 12 weeks. Female participants who are pregnant, breast-feeding or who plan to become pregnant during the study are not allowed to participate in the study. Pregnancy will be checked by blood or urine tests during the study.

Conditions

  • Overweight , Obesity

Interventions

  • ZT006Drug

    Participants will receive a daily dose of ZT006

  • Placebo of ZT006Drug

    Participants will receive a daily dose of placebo of ZT006

  • ZT006Drug

    Participants will receive a weekly dose of ZT006

  • ZT006Drug

    Participants will receive a weekly dose of ZT006

  • ZT006Drug

    Participants will receive a weekly dose of ZT006

  • ZT006Drug

    Participants will receive a weekly dose of ZT006

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in body weight relative to baselineTime frame: Percentage-point from baseline to end of treatment (week 28)of the main study
  2. Rate of treatment-emergent adverse events in the extension periodTime frame: From week 28 to week 45
  3. Rate of serious adverse events in the extension periodTime frame: From week 28 to week 45

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China

  • Handan First Hospital

    Handan, Hebei, China

  • Hebei Petro China Central Hospital

    Langfang, Hebei, China

  • Harbin Medical University Affiliated Fourth Hospital

    Harbin, Heilongjiang, China

  • Luoyang Third People's Hospital

    Luoyang, Henan, China

  • The First People's Hospital of Chenzhou

    Chenzhou, Hunan, China

  • YueYang People's Hospital

    Yueyang, Hunan, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

  • Central Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Xi'an Daxing Hospital

    Xi’an, Shanxi, China

  • Huzhou Central Hospital

    Huzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.